JP7631193B2 - Tyk2阻害剤およびその使用 - Google Patents

Tyk2阻害剤およびその使用 Download PDF

Info

Publication number
JP7631193B2
JP7631193B2 JP2021523157A JP2021523157A JP7631193B2 JP 7631193 B2 JP7631193 B2 JP 7631193B2 JP 2021523157 A JP2021523157 A JP 2021523157A JP 2021523157 A JP2021523157 A JP 2021523157A JP 7631193 B2 JP7631193 B2 JP 7631193B2
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
heterocycloalkyl
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021523157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505987A5 (cg-RX-API-DMAC7.html
JP2022505987A (ja
Inventor
ジン,ボアン
ドン,チン
ハン,ジーン
ダブリュ. カルドア,スティーブン
Original Assignee
アルミス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルミス インコーポレイテッド filed Critical アルミス インコーポレイテッド
Publication of JP2022505987A publication Critical patent/JP2022505987A/ja
Publication of JP2022505987A5 publication Critical patent/JP2022505987A5/ja
Priority to JP2025017826A priority Critical patent/JP2025090577A/ja
Application granted granted Critical
Publication of JP7631193B2 publication Critical patent/JP7631193B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
JP2021523157A 2018-10-22 2019-10-22 Tyk2阻害剤およびその使用 Active JP7631193B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017826A JP2025090577A (ja) 2018-10-22 2025-02-05 Tyk2阻害剤およびその使用

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201862749003P 2018-10-22 2018-10-22
US62/749,003 2018-10-22
US201862756942P 2018-11-07 2018-11-07
US62/756,942 2018-11-07
US201962839459P 2019-04-26 2019-04-26
US62/839,459 2019-04-26
US201962875449P 2019-07-17 2019-07-17
US62/875,449 2019-07-17
US201962893721P 2019-08-29 2019-08-29
US62/893,721 2019-08-29
US201962907354P 2019-09-27 2019-09-27
US62/907,354 2019-09-27
PCT/US2019/057485 WO2020086616A1 (en) 2018-10-22 2019-10-22 Tyk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017826A Division JP2025090577A (ja) 2018-10-22 2025-02-05 Tyk2阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2022505987A JP2022505987A (ja) 2022-01-14
JP2022505987A5 JP2022505987A5 (cg-RX-API-DMAC7.html) 2022-10-28
JP7631193B2 true JP7631193B2 (ja) 2025-02-18

Family

ID=70330735

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523157A Active JP7631193B2 (ja) 2018-10-22 2019-10-22 Tyk2阻害剤およびその使用
JP2025017826A Pending JP2025090577A (ja) 2018-10-22 2025-02-05 Tyk2阻害剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017826A Pending JP2025090577A (ja) 2018-10-22 2025-02-05 Tyk2阻害剤およびその使用

Country Status (26)

Country Link
US (6) US11053219B2 (cg-RX-API-DMAC7.html)
EP (4) EP3870579B1 (cg-RX-API-DMAC7.html)
JP (2) JP7631193B2 (cg-RX-API-DMAC7.html)
KR (1) KR102850357B1 (cg-RX-API-DMAC7.html)
CN (1) CN113490664B (cg-RX-API-DMAC7.html)
AU (1) AU2019364336B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021007679A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117200A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000989A1 (cg-RX-API-DMAC7.html)
DK (3) DK4480953T3 (cg-RX-API-DMAC7.html)
ES (3) ES3069897T3 (cg-RX-API-DMAC7.html)
FI (3) FI3870579T3 (cg-RX-API-DMAC7.html)
HR (3) HRP20260578T1 (cg-RX-API-DMAC7.html)
HU (1) HUE070644T2 (cg-RX-API-DMAC7.html)
IL (1) IL282487B2 (cg-RX-API-DMAC7.html)
LT (3) LT3870579T (cg-RX-API-DMAC7.html)
MX (1) MX2021004538A (cg-RX-API-DMAC7.html)
PL (3) PL3870579T3 (cg-RX-API-DMAC7.html)
PT (3) PT4480953T (cg-RX-API-DMAC7.html)
RS (3) RS66346B1 (cg-RX-API-DMAC7.html)
SA (1) SA521421806B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202104017VA (cg-RX-API-DMAC7.html)
SI (3) SI3870579T1 (cg-RX-API-DMAC7.html)
SM (3) SMT202600191T1 (cg-RX-API-DMAC7.html)
UA (1) UA130518C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020086616A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025090577A (ja) * 2018-10-22 2025-06-17 アルミス インコーポレイテッド Tyk2阻害剤およびその使用

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3601268T (lt) * 2017-03-30 2021-05-25 Bristol-Myers Squibb Company 6-(ciklopropanamido)-4-((2-metoksi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3)piridazino-3-karboksamido gavimo būdas
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
CN111484480B (zh) * 2019-01-29 2023-08-11 上海翰森生物医药科技有限公司 一种多环类衍生物抑制剂、其制备方法和应用
WO2020159904A1 (en) * 2019-01-30 2020-08-06 Bristol-Myers Squibb Company Amide-disubstituted pyridine or pyridazine compounds
KR102865925B1 (ko) * 2019-03-05 2025-09-26 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
US12528782B2 (en) 2019-07-16 2026-01-20 Bristol-Myers Squibb Company Prodrugs in the modulation of interleukin
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
CN114846012B (zh) 2019-09-27 2024-01-26 武田药品工业株式会社 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物
US12606556B2 (en) 2020-02-26 2026-04-21 Beone Medicines I Gmbh TYK-2 inhibitor
ES2981764T3 (es) * 2020-03-11 2024-10-10 Beijing Innocare Pharma Tech Co Ltd Compuestos heterocíclicos para inhibir las actividades de TYK2
WO2021202652A1 (en) * 2020-04-01 2021-10-07 Eternity Bioscience Inc. Tyrosine kinase 2 inhibitors, preparation methods and medicinal uses thereof
US20230295119A1 (en) * 2020-04-14 2023-09-21 Gossamer Bio Services, Inc. Substituted pyridines for the treatment of inflammatory diseases
CN113563309B (zh) * 2020-04-28 2024-12-13 浙江海正药业股份有限公司 吡啶类衍生物及其制备方法和用途
CN113735837B (zh) * 2020-05-28 2023-09-01 江苏先声药业有限公司 哒嗪类化合物及其用途
CN113735836B (zh) * 2020-05-28 2023-05-30 江苏先声药业有限公司 哒嗪类化合物及其应用
CN113773262B (zh) * 2020-06-09 2024-08-09 江苏先声药业有限公司 哒嗪类化合物
US20240043435A1 (en) 2020-06-22 2024-02-08 Beigene, Ltd. Tyk-2 inhibitor
CN114057651B (zh) * 2020-07-31 2025-05-27 正大天晴药业集团股份有限公司 含酰胺基的tyk2抑制剂化合物
WO2022032484A1 (zh) * 2020-08-11 2022-02-17 北京诺诚健华医药科技有限公司 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用
WO2022033544A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CN114075220A (zh) * 2020-08-13 2022-02-22 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
IL301385A (en) 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
TW202227430A (zh) * 2020-11-17 2022-07-16 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類衍生物、其製備方法及其在醫藥上的應用
TWI912419B (zh) * 2020-12-02 2026-01-21 大陸商深圳微芯生物科技股份有限公司 羥肟酸酯化合物、其製備方法及其應用
CN116547276A (zh) * 2020-12-08 2023-08-04 正大天晴药业集团股份有限公司 含酰胺基和杂环烷基的tyk2抑制剂化合物
CN122520625A (zh) * 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
WO2022179578A1 (zh) * 2021-02-24 2022-09-01 南京明德新药研发有限公司 含有亚磺酰基吡啶结构的化合物以及应用
CN112920103A (zh) * 2021-03-02 2021-06-08 康化(上海)新药研发有限公司 一种温和制备2-氮杂螺[3.3]庚烷盐酸盐的方法
EP4308556A4 (en) * 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
CN115197196B (zh) * 2021-04-06 2024-06-18 扬子江药业集团有限公司 Tyk2抑制剂及其用途
CN116888125B (zh) * 2021-04-07 2024-04-12 上海齐鲁制药研究中心有限公司 Tyk2抑制剂及其用途
JP7740849B2 (ja) * 2021-05-04 2025-09-17 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
KR20240008338A (ko) * 2021-05-14 2024-01-18 브리스톨-마이어스 스큅 컴퍼니 치환된 헤테로시클릭 화합물
EP4337650A1 (en) * 2021-05-14 2024-03-20 Bristol-Myers Squibb Company Substituted heterocyclic compounds
WO2022253333A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 酰胺类化合物及其应用
WO2022253335A1 (zh) * 2021-06-02 2022-12-08 南京明德新药研发有限公司 含磺酰基的芳基类化合物及其应用
CN115466289B (zh) * 2021-06-11 2026-07-03 爱科诺生物医药(苏州)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
CA3223641A1 (en) * 2021-06-22 2022-12-29 Wenyuan Qian Sulfoximine compound and use thereof
CN117794911A (zh) * 2021-07-15 2024-03-29 南京明德新药研发有限公司 含硫/磷的芳基类化合物及其应用
TW202320786A (zh) * 2021-08-10 2023-06-01 美商蕾瑞拉股份有限公司 用於毛髮治療的組合物、調配物及方法
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
EP4410806A1 (en) * 2021-09-30 2024-08-07 ASKA Pharmaceutical Co., Ltd. Degradation inducer
WO2023064223A1 (en) * 2021-10-11 2023-04-20 Gossamer Bio Services, Inc. Tri-substituted pyridines
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
TW202339749A (zh) * 2021-12-16 2023-10-16 大陸商凌科藥業有限公司 Tyk2抑制劑及其組合物和方法
US20250051360A1 (en) * 2021-12-23 2025-02-13 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compound, and composition and use thereof
MX2024007713A (es) * 2021-12-23 2024-07-01 Beigene Switzerland Gmbh Formas solidas de un inhibidor de tyk2, metodo de preparacion y uso de estas.
CN116693449A (zh) 2022-03-04 2023-09-05 上海致根医药科技有限公司 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
TW202342000A (zh) 2022-03-29 2023-11-01 美商雅盧米斯公司 Tyk2抑制劑及其用途
US20260209205A1 (en) * 2022-05-13 2026-07-23 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof
AU2023283927A1 (en) * 2022-06-07 2024-08-15 Guangzhou Fermion Technology Co., Ltd. Substituted pyridazine-3-carboxamide compound serving as tyk2 inhibitor
WO2023236945A1 (zh) * 2022-06-07 2023-12-14 广州费米子科技有限责任公司 哒嗪-3-甲酰胺化合物作为tyk2抑制剂
AU2023294765A1 (en) * 2022-06-17 2024-12-12 Sundance Biosciences, Inc. Kinase modulators and methods of use thereof
CN120661462B (zh) * 2022-06-20 2026-05-26 益方生物科技(上海)股份有限公司 药物组合物及其用途
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
US20250376459A1 (en) * 2022-09-12 2025-12-11 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
US12251459B2 (en) 2022-10-12 2025-03-18 Oddity Labs, Llc Compositions, formulations, and methods for hair treatment
CN120152968A (zh) * 2022-11-08 2025-06-13 百时美施贵宝公司 取代的杂环化合物
WO2024123668A1 (en) * 2022-12-05 2024-06-13 Oddity Labs, Llc Compositions, formulations, and methods for hair treatment
TW202430168A (zh) 2022-12-16 2024-08-01 印度商阿蘭比克製藥有限公司 Tyk2假激酶配體及其用途
CN116284040B (zh) * 2023-01-05 2024-05-28 华润医药研究院(深圳)有限公司 含氮杂环类化合物及其医药用途
WO2024173764A1 (en) 2023-02-16 2024-08-22 Alumis Inc. Methods of treating hidradenitis suppurativa
WO2024257023A1 (en) * 2023-06-14 2024-12-19 Alembic Pharmaceuticals Limited Tyk2 pseudokinase ligands and uses thereof
CN121909018A (zh) 2023-09-20 2026-04-21 阿鲁米斯公司 Tyk2抑制剂的立即释放制剂
WO2025186427A1 (en) 2024-03-08 2025-09-12 Curia Spain, S.A.U. Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib
WO2025194074A1 (en) * 2024-03-15 2025-09-18 Neuron23, Inc. Kinase modulators and methods of use thereof
WO2025240835A2 (en) * 2024-05-17 2025-11-20 Prelude Therapeutics Incorporated Jak2 inhibitors and their use as pharmaceuticals
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof
TW202610624A (zh) * 2024-07-16 2026-03-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026026866A1 (zh) * 2024-08-02 2026-02-05 北京普祺医药科技股份有限公司 作为tyk2抑制剂的大环化合物及其药物组合物
WO2026092538A1 (zh) * 2024-10-29 2026-05-07 上海喆邺生物科技有限公司 含氮杂环类衍生物在制备治疗皮肤病药物中的用途
WO2026128621A2 (en) * 2024-12-12 2026-06-18 Alumis Inc. Process of making tyk2 inhibitors and uses thereof
WO2026136251A1 (en) 2024-12-16 2026-06-25 Alumis Inc. Tyk2 inhibitor for treating neuroinflammatory or neurodegenerative diseases

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105222A2 (en) 2005-03-25 2006-10-05 Scios Inc. Carboxamide inhibitors of tgfb
WO2010058846A1 (ja) 2008-11-21 2010-05-27 アステラス製薬株式会社 4,6-ジアミノニコチンアミド化合物
WO2010128659A1 (ja) 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
JP2011518157A (ja) 2008-04-16 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド Syk又はjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド類
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
JP2014501705A (ja) 2010-11-01 2014-01-23 ポートラ ファーマシューティカルズ, インコーポレイテッド Syk調節剤としてのベンズアミドおよびニコチンアミド
JP2015503575A (ja) 2012-01-10 2015-02-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリダジンアミド化合物及びsyk阻害剤としてのそれらの使用
WO2015030189A1 (ja) 2013-08-29 2015-03-05 京都薬品工業株式会社 新規芳香族化合物およびその用途
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
JP2016506369A (ja) 2012-11-08 2016-03-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物
JP2016539152A (ja) 2013-12-05 2016-12-15 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
JP2017512749A (ja) 2013-11-07 2017-05-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Il−12、il−23および/またはifnアルファ応答の調節因子として有用なアルキル−アミド−置換ピリジル化合物
JP2018522823A (ja) 2015-06-02 2018-08-16 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
WO2018165240A1 (en) 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US7517882B2 (en) 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
BR122019024201B1 (pt) 2010-05-20 2021-08-03 Array Biopharma Inc Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica
CN102250065B (zh) 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
PT2760453T (pt) 2011-09-30 2016-08-02 Ipsen Pharma Sas Inibidores macrocíclicos da cinase lrrk2
US9701689B2 (en) 2012-11-30 2017-07-11 Kyowa Hakko Kirin Co., Ltd. Substituted pyridines and pyridazines as CCR10 receptor inhibitors
WO2014140299A1 (en) 2013-03-15 2014-09-18 Oncodesign S.A Macrocyclic rip2 kinase inhibitors
WO2015112806A2 (en) 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
CN105111151B (zh) 2015-04-17 2018-09-28 成都理工大学 作为PPAR-γ调节剂的氨基嘧啶衍生物
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
WO2017015367A1 (en) 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
KR102782807B1 (ko) 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
EP3405464B1 (en) 2016-01-22 2019-12-04 Janssen Pharmaceutica NV New 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors
AU2017302019A1 (en) 2016-07-28 2019-02-07 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
US10836770B2 (en) 2016-10-07 2020-11-17 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018112027A1 (en) 2016-12-14 2018-06-21 Development Center For Biotechnology Antibody-drug conjugates and uses thereof
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
CN106866660B (zh) 2017-02-15 2019-05-17 上海天马有机发光显示技术有限公司 电子传输材料、包含其的oled显示面板和电子设备
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018186366A1 (ja) 2017-04-03 2018-10-11 京都薬品工業株式会社 新規サイクリン依存性キナーゼ8及び/又は19阻害剤
WO2018234345A1 (en) 2017-06-21 2018-12-27 F. Hoffmann-La Roche Ag PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4
PT3658148T (pt) 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
WO2019049891A1 (ja) 2017-09-06 2019-03-14 小野薬品工業株式会社 Trk阻害剤とキナーゼ阻害剤の併用による癌治療方法
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
WO2019084499A1 (en) 2017-10-27 2019-05-02 Genea Biocells USA (Holdings), Inc. INHIBITORS OF DUX4 INDUCTION FOR REGULATION OF MUSCLE FUNCTION
CA3081790C (en) 2017-11-10 2023-03-07 Angex Pharmaceutical, Inc. Macrocyclic compounds as trk kinase inhibitors and uses thereof
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
WO2019144885A1 (zh) 2018-01-23 2019-08-01 深圳市塔吉瑞生物医药有限公司 取代的吡唑并[1,5-a]嘧啶类的大环化合物
WO2019165967A1 (zh) 2018-02-28 2019-09-06 南京明德新药研发有限公司 吡唑并嘧啶衍生物及其用途
EP3773725A1 (en) 2018-03-29 2021-02-17 Loxo Oncology Inc. Treatment of trk-associated cancers
CN109053682B (zh) 2018-07-27 2020-10-27 东南大学 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
CA3126034A1 (en) 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
KR102943760B1 (ko) 2019-01-28 2026-03-26 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도
SG11202108619SA (en) 2019-02-07 2021-09-29 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
US20220177486A1 (en) 2019-03-11 2022-06-09 Esker Therapeutics, Inc. Tyk2 inhibitors and uses thereof
SG11202110523XA (en) 2019-03-26 2021-10-28 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
CN114929226B (zh) 2019-11-08 2024-09-27 温缇克斯生物科学公司 Tyk2假激酶配体

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105222A2 (en) 2005-03-25 2006-10-05 Scios Inc. Carboxamide inhibitors of tgfb
JP2011518157A (ja) 2008-04-16 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド Syk又はjakキナーゼ阻害剤としての2,6−ジアミノ−ピリミジン−5−イル−カルボキサミド類
WO2010058846A1 (ja) 2008-11-21 2010-05-27 アステラス製薬株式会社 4,6-ジアミノニコチンアミド化合物
WO2010128659A1 (ja) 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
JP2014501705A (ja) 2010-11-01 2014-01-23 ポートラ ファーマシューティカルズ, インコーポレイテッド Syk調節剤としてのベンズアミドおよびニコチンアミド
JP2015503575A (ja) 2012-01-10 2015-02-02 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ピリダジンアミド化合物及びsyk阻害剤としてのそれらの使用
JP2016506369A (ja) 2012-11-08 2016-03-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company IL−12、IL−23および/またはIFNα応答のモジュレーターとして有用なアミド置換ヘテロ環式化合物
WO2015030189A1 (ja) 2013-08-29 2015-03-05 京都薬品工業株式会社 新規芳香族化合物およびその用途
JP2017512749A (ja) 2013-11-07 2017-05-25 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Il−12、il−23および/またはifnアルファ応答の調節因子として有用なアルキル−アミド−置換ピリジル化合物
JP2016539152A (ja) 2013-12-05 2016-12-15 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
WO2015123453A1 (en) 2014-02-14 2015-08-20 Portola Pharmaceuticals, Inc. Pyridazine compounds as jak inhibitors
JP2018522823A (ja) 2015-06-02 2018-08-16 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
WO2018165240A1 (en) 2017-03-08 2018-09-13 Nimbus Lakshmi, Inc. Tyk2 inhibitors, uses, and methods for production thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Coffey, Greg; et al.,Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.,Journal of Pharmacology and Experimental Therapeutics ,2012年,340(2),p.350-359
Xu, Shilin; et al.,Design, synthesis and biological evaluation of new molecules inhibiting epidermal growth factor receptor threonine790 methionine790 mutant.,MedChemComm,2012年,3(9),p.1155-1159

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025090577A (ja) * 2018-10-22 2025-06-17 アルミス インコーポレイテッド Tyk2阻害剤およびその使用

Also Published As

Publication number Publication date
EP4461734A3 (en) 2024-12-11
US20230023761A1 (en) 2023-01-26
HRP20260578T1 (hr) 2026-06-19
LT3870579T (lt) 2025-01-27
IL282487B2 (en) 2026-07-01
FI4480953T3 (fi) 2026-04-30
HUE070644T2 (hu) 2025-06-28
US20230021554A1 (en) 2023-01-26
US20200354338A1 (en) 2020-11-12
WO2020086616A1 (en) 2020-04-30
US12351572B2 (en) 2025-07-08
EP3870579A4 (en) 2022-10-19
EP4480953A3 (en) 2025-02-19
RS68029B1 (sr) 2026-05-29
SG11202104017VA (en) 2021-05-28
KR20210095634A (ko) 2021-08-02
DK3870579T3 (da) 2025-01-02
ES3069897T3 (en) 2026-06-11
CL2021000989A1 (es) 2021-10-29
CA3117200A1 (en) 2020-04-30
DK4480953T3 (da) 2026-04-20
US11731956B2 (en) 2023-08-22
SA521421806B1 (ar) 2024-11-20
US12006306B2 (en) 2024-06-11
PL4480953T3 (pl) 2026-07-27
EP4480953B1 (en) 2026-02-04
PT4461734T (pt) 2026-05-04
CN113490664B (zh) 2025-05-16
SMT202500070T1 (it) 2025-03-12
SI3870579T1 (sl) 2025-03-31
AU2019364336B2 (en) 2023-11-16
ES3011855T3 (en) 2025-04-08
BR112021007679A2 (pt) 2021-07-27
SI4461734T1 (sl) 2026-06-30
HRP20260580T1 (hr) 2026-06-19
JP2022505987A (ja) 2022-01-14
FI3870579T3 (fi) 2025-01-02
EP4461734A2 (en) 2024-11-13
JP2025090577A (ja) 2025-06-17
PL3870579T3 (pl) 2025-03-17
SI4480953T1 (sl) 2026-06-30
UA130518C2 (uk) 2026-03-11
AU2019364336A1 (en) 2021-05-27
FI4461734T3 (fi) 2026-04-29
SMT202600190T1 (it) 2026-05-12
CN113490664A (zh) 2021-10-08
KR102850357B1 (ko) 2025-08-27
US12060343B2 (en) 2024-08-13
EP4763208A2 (en) 2026-06-24
MX2021004538A (es) 2021-09-10
LT4461734T (lt) 2026-06-10
LT4480953T (lt) 2026-06-10
US20230391751A1 (en) 2023-12-07
EP4480953A2 (en) 2024-12-25
HRP20250048T1 (hr) 2025-03-28
US20260125361A1 (en) 2026-05-07
PT4480953T (pt) 2026-05-08
SMT202600191T1 (it) 2026-05-12
EP3870579A1 (en) 2021-09-01
US11053219B2 (en) 2021-07-06
PL4461734T3 (pl) 2026-07-27
DK4461734T3 (da) 2026-04-20
RS66346B1 (sr) 2025-01-31
RS68048B1 (sr) 2026-05-29
PT3870579T (pt) 2025-01-27
IL282487A (en) 2021-06-30
EP4461734B1 (en) 2026-02-04
ES3069896T3 (en) 2026-06-11
US20220235035A1 (en) 2022-07-28
IL282487B1 (en) 2026-03-01
EP3870579B1 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP2025090577A (ja) Tyk2阻害剤およびその使用
KR102899985B1 (ko) Tyk2 억제제 및 그의 용도
CN101305005A (zh) 新二氮杂螺烷以及它们用于治疗ccr8介导的疾病的用途
KR20230069984A (ko) Tyk2 억제제 및 그의 용도
CN115043836B (zh) 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途
RU2813233C2 (ru) Ингибиторы tyk2 и пути их применения
HK40065275A (zh) Tyk2抑制剂和其用途
HK40119624B (en) Tyk2 inhibitors and uses thereof
HK40120037B (en) Tyk2 inhibitors and uses thereof
HK40065275B (en) Tyk2 inhibitors and uses thereof
HK40119624A (en) Tyk2 inhibitors and uses thereof
HK40120037A (en) Tyk2 inhibitors and uses thereof
HK40063819A (en) Tyk2 inhibitors and uses thereof
HK40070149A (en) Dosage forms and regimens for amino acid compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241105

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250205

R150 Certificate of patent or registration of utility model

Ref document number: 7631193

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150